Document is current
Any future updates will be listed below
-
Authors
Wiggins, Kimberly T.
Hall, Tristen L.
Jortberg, Bonnie
Dickinson, W. Perry
Dickinson, L. Miriam
Parascando, Jessica A.
Fernald, Douglas H.
Sobczak, Chelsea
Oser, Sean M.
Oser, Tamara K.
-
Funding
Funding for this research was provided by:
Leona M. and Harry B. Helmsley Charitable Trust
National Center for Advancing Translational Sciences (UL1 TR002535, UL1 TR002535, UL1 TR002535, UL1 TR002535, UL1 TR002535, UL1 TR002535, UL1 TR002535, UL1 TR002535, UL1 TR002535, UL1 TR002535)
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 27 May 2025
First Online: 9 June 2025
Declarations
:
: This project was reviewed and approved by the Colorado Multiple Institutional Review Board (COMIRB; Protocol 21-4269) and registered with ClinicalTrials.gov (NCT05336214). Individual participants provided written informed consent to participate. This study adhered to the ethical principles of the Declaration of Helsinki.
: Not applicable.
: TO and SO have served as Advisory Board Consultants (fees paid to the University of Colorado) for Dexcom, MedScape (more than 12 months ago), and Blue Circle Health. They have received research grants and contracts (through the University of Colorado) from NINR, NIDDK, the Helmsley Charitable Trust, Abbott Diabetes, Dexcom, and Insulet. They do not own stocks in any device or pharmaceutical company. All other authors report none.
